All In Biotech

NDA 218038 · Hq Spclt Pharma

Diltiazem Hydrochloride In 0.72% Sodium Chloride

Diltiazem Hydrochloride · Intravenous

Last checked: Nov 19, 2026Latest source record: Feb 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Feb 21, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

127

21 Phase 3, 6 recruiting

FAERS reports

11,574

9,725 serious, 2,765 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 15, 2025.

Diltiazem Hydrochloride in Sodium Chloride Injection is a non-dihydropyridine calcium-channel blocker indicated for the following: • Temporary control of rapid ventricular rate in atrial fibrillation or atrial flutter. ( 1.1) • Rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm. ( 1.2 ) 1.1 Atrial Fibrillation or Atrial Flutter Diltiazem Hydrochloride in Sodium Chloride Injection is indicated in adults for the temporary control of rapid ventricular rate in atrial fibrillation or atrial flutter. 1.2 Paroxysmal Supraventricular Tachycardia Diltiazem Hydrochloride in Sodium Chloride Injection is indicated in adults for rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm.

Mechanism: The therapeutic effects of diltiazem are believed to be related to inhibiting influx of calcium ions during membrane depolarization of cardiac and vascular smooth muscle. Paroxysmal Supraventricular Tachycardia: Diltiazem slows AV nodal conduction time and prolongs AV nodal refractoriness. Diltiazem exhibits frequency- (use-) dependent effects on AV nodal conduction such that it may selectively reduce the heart rate during tachycardias involving the AV node with little or no effect on normal AV nodal conduction at normal heart rates. Atrial Fibrillation or Atrial Flutter : Diltiazem slows the...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 21, 2025 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
2 products under this application
  • DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE · DILTIAZEM HYDROCHLORIDE 250MG/250ML (1MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE · DILTIAZEM HYDROCHLORIDE 100MG/100ML (1MG/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Diltiazem" as an intervention, any sponsor and status, largest first.

All 127 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea1,345
  • pain1,211
  • fatigue1,162
  • fall1,056
  • arthralgia921
  • diarrhoea912
  • headache904
  • dizziness899
  • nausea871
  • pruritus870
  • pyrexia844
  • drug ineffective843

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004381
2005388
2006235
2007173
2008185
2009169
2010220
2011192
2012310
2013282
2014210
2015256
2016297
2017311
2018312
2019358
2020519
2021873
20221,421
20231,092
20241,322
20251,294
2026774

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,211 on PubMed

Sponsor: Hq Spclt Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.